Wei Zhao1, Xueyin Wang1,2, Amy A Deik3, David B Hanna1, Tao Wang1, Sabina A Haberlen4, Sanjiv J Shah5, Jason M Lazar6, Howard N Hodis7, Alan L Landay8, Bing Yu9, Deborah Gustafson6, Kathryn Anastos1, Wendy S Post10, Clary B Clish3, Robert C Kaplan1,11, Qibin Qi. 1. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (W.Z., X.W., D.B.H., T.W., K.A., R.C.K.). 2. Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China (X.W.). 3. Broad Institute of MIT and Harvard, Cambridge, MA (A.A.D., C.B.C.). 4. Department of Epidemiology (S.A.H.), Johns Hopkins University, Baltimore, MD. 5. Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.). 6. Department of Neurology, State University of New York-Downstate Medical Center, Brooklyn (J.M.L., D.G.). 7. Atherosclerosis Research Unit, Keck School of Medicine, University of Southern California, Los Angeles (H.N.H.). 8. Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, IL (A.L.L.). 9. Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, the University of Texas Health Science Center, Houston (B.Y.). 10. Division of Cardiology, Department of Medicine (W.S.P.), Johns Hopkins University, Baltimore, MD. 11. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (R.C.K.).
Abstract
BACKGROUND: Ceramides have been implicated in the pathophysiology of HIV infection and cardiovascular disease. However, no study, to our knowledge, has evaluated circulating ceramide levels in association with subclinical cardiovascular disease risk among HIV-infected individuals. METHODS: Plasma levels of 4 ceramide species (C16:0, C22:0, C24:0, and C24:1) were measured among 398 women (73% HIV+) and 339 men (68% HIV+) without carotid artery plaques at baseline from the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. We examined associations between baseline plasma ceramides and risk of carotid artery plaque formation, assessed by repeated B-mode carotid artery ultrasound imaging over a median 7-year follow-up. RESULTS: Plasma levels of C16:0, C22:0, and C24:1 ceramides were significantly higher in HIV-infected individuals compared with those without HIV infection (all P<0.001), and further analysis indicated that elevated ceramide levels were associated with antiretroviral therapy use, particularly protease inhibitor use, in HIV-infected individuals (all P<0.001). All 4 ceramides were highly correlated with each other ( r=0.70-0.94; all P<0.001) and significantly correlated with total-cholesterol ( r=0.42-0.58; all P<0.001) and low-density lipoprotein cholesterol ( r=0.24-0.42; all P<0.001) levels. Of note, C16:0 and C24:1 ceramides, rather than C22:0 and C24:0 ceramides, were more closely correlated with specific monocyte activation and inflammation markers (eg, r=0.30 between C16:0 ceramide and soluble CD14; P<0.001) and surface markers of CD4+ T-cell activation. A total of 112 participants developed carotid artery plaques over 7 years, and higher levels of C16:0 and C24:1 ceramides were significantly associated with increased risk of carotid artery plaques (relative risk [95% CI]=1.55 [1.29, 1.86] and 1.51 [1.26, 1.82] per standard deviation increment, respectively; both P<0.001), after adjusting for demographic and behavioral factors. After further adjustment for cardiovascular disease risk factors and immune activation markers, these associations were attenuated but remained significant. The results were consistent between men and women and between HIV-infected and HIV-uninfected participants. CONCLUSIONS: In 2 HIV cohorts, elevated plasma levels of C16:0 and C24:1 ceramides, correlating with immune activation and inflammation, were associated with antiretroviral therapy use and progression of carotid artery atherosclerosis.
BACKGROUND: Ceramides have been implicated in the pathophysiology of HIV infection and cardiovascular disease. However, no study, to our knowledge, has evaluated circulating ceramide levels in association with subclinical cardiovascular disease risk among HIV-infected individuals. METHODS: Plasma levels of 4 ceramide species (C16:0, C22:0, C24:0, and C24:1) were measured among 398 women (73% HIV+) and 339 men (68% HIV+) without carotid artery plaques at baseline from the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. We examined associations between baseline plasma ceramides and risk of carotid artery plaque formation, assessed by repeated B-mode carotid artery ultrasound imaging over a median 7-year follow-up. RESULTS: Plasma levels of C16:0, C22:0, and C24:1 ceramides were significantly higher in HIV-infected individuals compared with those without HIV infection (all P<0.001), and further analysis indicated that elevated ceramide levels were associated with antiretroviral therapy use, particularly protease inhibitor use, in HIV-infected individuals (all P<0.001). All 4 ceramides were highly correlated with each other ( r=0.70-0.94; all P<0.001) and significantly correlated with total-cholesterol ( r=0.42-0.58; all P<0.001) and low-density lipoprotein cholesterol ( r=0.24-0.42; all P<0.001) levels. Of note, C16:0 and C24:1 ceramides, rather than C22:0 and C24:0 ceramides, were more closely correlated with specific monocyte activation and inflammation markers (eg, r=0.30 between C16:0 ceramide and soluble CD14; P<0.001) and surface markers of CD4+ T-cell activation. A total of 112 participants developed carotid artery plaques over 7 years, and higher levels of C16:0 and C24:1 ceramides were significantly associated with increased risk of carotid artery plaques (relative risk [95% CI]=1.55 [1.29, 1.86] and 1.51 [1.26, 1.82] per standard deviation increment, respectively; both P<0.001), after adjusting for demographic and behavioral factors. After further adjustment for cardiovascular disease risk factors and immune activation markers, these associations were attenuated but remained significant. The results were consistent between men and women and between HIV-infected and HIV-uninfected participants. CONCLUSIONS: In 2 HIV cohorts, elevated plasma levels of C16:0 and C24:1 ceramides, correlating with immune activation and inflammation, were associated with antiretroviral therapy use and progression of carotid artery atherosclerosis.
Entities:
Keywords:
HIV infections; association; atherosclerosis; lipids
Authors: Dong D Wang; Estefanía Toledo; Adela Hruby; Bernard A Rosner; Walter C Willett; Qi Sun; Cristina Razquin; Yan Zheng; Miguel Ruiz-Canela; Marta Guasch-Ferré; Dolores Corella; Enrique Gómez-Gracia; Miquel Fiol; Ramón Estruch; Emilio Ros; José Lapetra; Montserrat Fito; Fernando Aros; Luis Serra-Majem; Chih-Hao Lee; Clary B Clish; Liming Liang; Jordi Salas-Salvadó; Miguel A Martínez-González; Frank B Hu Journal: Circulation Date: 2017-03-09 Impact factor: 29.690
Authors: Virginia A Triant; Jeremiah Perez; Susan Regan; Joseph M Massaro; James B Meigs; Steven K Grinspoon; Ralph B D'Agostino Journal: Circulation Date: 2018-02-14 Impact factor: 29.690
Authors: P-J Touboul; M G Hennerici; S Meairs; H Adams; P Amarenco; N Bornstein; L Csiba; M Desvarieux; S Ebrahim; R Hernandez Hernandez; M Jaff; S Kownator; T Naqvi; P Prati; T Rundek; M Sitzer; U Schminke; J-C Tardif; A Taylor; E Vicaut; K S Woo Journal: Cerebrovasc Dis Date: 2012-11-01 Impact factor: 2.762
Authors: Qibin Qi; Simin Hua; Clary B Clish; Justin M Scott; David B Hanna; Tao Wang; Sabina A Haberlen; Sanjiv J Shah; Marshall J Glesby; Jason M Lazar; Robert D Burk; Howard N Hodis; Alan L Landay; Wendy S Post; Kathryn Anastos; Robert C Kaplan Journal: Clin Infect Dis Date: 2018-07-02 Impact factor: 9.079
Authors: Aki S Havulinna; Marko Sysi-Aho; Mika Hilvo; Dimple Kauhanen; Reini Hurme; Kim Ekroos; Veikko Salomaa; Reijo Laaksonen Journal: Arterioscler Thromb Vasc Biol Date: 2016-10-20 Impact factor: 8.311
Authors: Robert C Kaplan; Elizabeth Sinclair; Alan L Landay; Nell Lurain; A Richey Sharrett; Stephen J Gange; Xiaonan Xue; Peter Hunt; Roksana Karim; David M Kern; Howard N Hodis; Steven G Deeks Journal: J Infect Dis Date: 2011-01-10 Impact factor: 5.226
Authors: Monty Montano; Shalender Bhasin; Richard T D'Aquila; Kristine M Erlandson; William J Evans; Nicholas T Funderburg; Amy Justice; Lishomwa C Ndhlovu; Bisola Ojikutu; Marco Pahor; Savita Pahwa; Alice S Ryan; Jennifer Schrack; Michael B Schultz; Paola Sebastiani; David A Sinclair; Julia Tripp; Bruce Walker; Julie A Womack; Raymond Yung; R Keith Reeves Journal: AIDS Res Hum Retroviruses Date: 2019-09-23 Impact factor: 2.205
Authors: Juho-Pekka Karjalainen; Nina Mononen; Nina Hutri-Kähönen; Miikael Lehtimäki; Mika Hilvo; Dimple Kauhanen; Markus Juonala; Jorma Viikari; Mika Kähönen; Olli Raitakari; Reijo Laaksonen; Terho Lehtimäki Journal: J Lipid Res Date: 2019-07-03 Impact factor: 5.922
Authors: Zheng Wang; Brandilyn A Peters; Mykhaylo Usyk; Jiaqian Xing; David B Hanna; Tao Wang; Wendy S Post; Alan L Landay; Howard N Hodis; Kathleen Weber; Audrey French; Elizabeth T Golub; Jason Lazar; Deborah Gustafson; Seble Kassaye; Bradley Aouizerat; Sabina Haberlen; Carlos Malvestutto; Matthew Budoff; Steven M Wolinsky; Anjali Sharma; Kathryn Anastos; Clary B Clish; Robert C Kaplan; Robert D Burk; Qibin Qi Journal: Arterioscler Thromb Vasc Biol Date: 2022-06-09 Impact factor: 10.514
Authors: Guo-Chong Chen; Jin Choul Chai; Bing Yu; Gregory A Michelotti; Megan L Grove; Amanda M Fretts; Martha L Daviglus; Olga L Garcia-Bedoya; Bharat Thyagarajan; Neil Schneiderman; Jianwen Cai; Robert C Kaplan; Eric Boerwinkle; Qibin Qi Journal: Am J Clin Nutr Date: 2020-07-01 Impact factor: 7.045
Authors: Jin Choul Chai; Amy A Deik; Simin Hua; Tao Wang; David B Hanna; Xiaonan Xue; Sabina A Haberlen; Sanjiv J Shah; Yousin Suh; Jason M Lazar; Deborah Gustafson; Howard N Hodis; Alan L Landay; Kathryn Anastos; Wendy S Post; Robert C Kaplan; Clary B Clish; Qibin Qi Journal: JAMA Cardiol Date: 2019-12-01 Impact factor: 30.154